Irwin Mitchell has advised APIS Assay Technologies Ltd on the deal.
APIS Assay Technologies acquired Beogenomics, a specialised software developer with major expertise in Bioinformatics and Artificial Intelligence (BIOX).
APIS develops new tests for the prediction, prevention, and diagnosis of disease from discovery to regulatory approval. The company’s business model is based on three pillars: biomarker diagnostics development, molecular diagnostic contract development, and applied bioinformatics.
Beogenomics has been developing both on-prem and secure cloud-based data analysis solutions – helping customers design, build and run custom tailored genomics & proteomics pipelines.
The start-up with amazing capability will be integrated into Manchester-based APIS, supporting the launch of a new BIOX Service Line as part of the company’s ongoing Biomarker Research and Development activities.
Bioinformatics and Artificial Intelligence are key competencies adding value to APIS’ in-house capabilities and expanding APIS’ service offer profile. Using AI-enabled data mining, the company aims to identify novel biomarkers, targeting oncology, inflammatory, autoimmune, infectious disease, and inherited disease areas.
Victoria Zivkovic (Picture), Corporate partner at Irwin Mitchell in Manchester, advised APIS Assay Technologies Ltd.
Involved fees earner: Victoria Zivkovic – Irwin Mitchell;
Law Firms: Irwin Mitchell;
Clients: APIS Assay Technologies Ltd;